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Accepted 11 September 2016Introduction: MPAL (Multi Phenotypic Acute Leukemia), BAL (Biphenotypic Acute Leukemia), AUL (Acute
Undifferentiated Leukemia), ALAL (Acute Leukemia of Ambiguous Lineage), HAL (Hybrid Acute Leukemia),
HAL (Hybrid Acute Leukemia),MLL (Mixed Lineage Leukemia) and aBLL (acute BiLineal Leukemia) represent
different names of the same pathology or do these entities represent completely separate disease processes?
These rather uncommon manifestations of acute leukemia complicate strict taxonomical sub grouping as well
as their management. Rapid identiﬁcation & swift management may restrict further neurological damage,
while achieving hematological remission.
Case description: A 16 year female presented with gradual onset paraplegia for 7 months, a history of multiple
blood transfusions in the past 2 years, pancytopenia, atypical cells in peripheral smear; the hematological and
bone marrow work up revealed a diagnosis of: MPAL, B/Myeloid, NOS [Multi Phenotypic Acute Leukemia, B
cell {lymphoid}/Myeloid, not otherwise speciﬁed]. An ALL type induction regimenwas started. Themanagement
strategy, it's rationale and the clinical outcome are discussed.
Conclusion: For routine neurosurgical practice, these entities are extremely rare; and hence aworking knowledge
is very essential for appropriate & timely management notwithstanding the neurosurgical desire to rule out the
compressive lesions ﬁrst. Neurological status deterioration may be halted with timely institution of appropriate
chemotherapy. In the extensive literature review in pubmed, this may be only the 1st case of MPAL with
extramedullary neurological manifestation, at the ﬁrst clinical presentation.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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MPAL (Multi Phenotypic Acute Leukemia),BAL (Biphenotypic Acute
Leukemia), AUL (Acute Undifferentiated Leukemia), ALAL (Acute Leu-
kemia of Ambiguous Lineage), HAL (Hybrid Acute Leukemia), MLL
(Mixed Lineage Leukemia) and aBLL (acute BiLineal Leukemia): -
these are some of the descriptive terms used to describe this rather
rare acute leukemias where there is either expansion of more than
one clone of progenitor cells or expression of multi lineage
immunophenotypic [B/ T/ Myeloid] markers. But how to deﬁne & char-
acterize these leukemias? WHO (World Health Organization) mono-
graph on acute leukemia in 2008 has tried to answer these queries by
deﬁning the term “MPAL (Multi Phenotypic Acute Leukemia)”. Still
the older jargons persist in the current literature, putting a systematic
literature review into serious difﬁculty and thereby complicating the
‘Optimal management’ of such cases.
1.1. Case description
A sixteen year old female (Fig.1) presentedwith prostration, gradual
progressive weakness of both the lower limbs for 7 months & inability
to get up in the bed without support. She also had sacral bedsores d/t
prolonged immobilization. Her highermental function,motor & sensory
examination of bilateral upper limb, examination of cranial nerves, and
examination of cerebellar and autonomic nervous system functionwere
within the normal limit. Motor system examination of the lower limbs
revealed: power to be 0/5 bilaterally (MRC-Medical research Council
scale), generalized hypertonia, exaggerated knee & ankle jerks and bi-
lateral ankle clonus. Bilateral plantar reﬂexes were extensor, abdominal
reﬂexes were normal; straight leg raising test couldn't be performed.
She had no meningeal signs; examination of skull & spine revealed
no abnormality except mild tenderness in the dorsolumbar spine. She
had diffuse tenderness all over her sternum throughout her illness.
Lower limbweakness & spinal tenderness were treated at some periph-
eral hospital as a case of an acute spinal compressive pathology & re-
ferred to us; but the pain never subsided with the prescribed analgesic
medications.
She had undergone magnetic resonance imaging (MRI) of the
dorsolumbar spine, prior to coming to our centre, which depicted a
D11–D12 non enhancing T1 iso & T2mildly hyperintense space occupy-
ing lesion, present extradurally & compressing the bilateral exiting
nerve roots foramina, with restriction diffusion on DWI (diffusion
weighted imaging) studies.
On further enquiry, she reported a past history of having 3 units of
blood transfusion in the past 2 years for her generalized weakness.
The cause of the transfusionswas notmentioned in the past medical re-
cords. A peripheral blood smear examinationwas done and hematology
consultation was sought. The peripheral smear showed hypochromicFig. 1. The patient LS, 16/F.poikilocytic anemia, normal thrombocyte cont and plenty of abnormal
cells.
Subsequent bonemarrow study (Fig. 2) revealed:
1) Hypercellular marrow with suppressed & normoblastic
erythropoiesis
2) Suppressed megakaryocytosis
3) Accelerated lymphocytosis and suppressed leukopoiesis showing;
-a) Myelo & metamyelocytic leukocytes with few myeloblasts
-b) Dominated blasts (60%) of marrow nucleated cells.
4) MPO (Myeloperoxidase stains) was negative in most of the cells.
Differential diagnoses from the above clinical features, hematolog-
ical & bone marrow work up were:
1. MPAL [Mixed phenotypic acute leukemia]
2. ALL-L2 [Acute Lymphocytic leukemia-L2 type].
An immunophenotyping was advised to conﬁrm the diagnosis,
which showed: CD45 (Cluster differentiation markers) = 68.06% of
gated leucocytes. T cell [CD5 = 1.12%, CD7 = 3.06%]. B cell [CD 10 =
0.05%, CD 19 = 83.06%]. Myeloid/monocytic [CD 13 = 92.38%,
CD33 = 88.40%, CD 117 = 68.36%]. Cytoplasmic [cCD3 = 0.01%,
Ccd79a = 98.36%, cAnti MPO = 81.08%]. Others [CD34 = 94.04%, HLA
(Human Leukocyte Antigen) DR = 68.93%].
Hence, theﬁnal diagnosiswasMPAL, B/Myeloid, NOS (Multi Pheno-
typic Acute Leukemia, B cell {lymphoid}/myeloid, not otherwise
speciﬁed).
In cases of BAL, cytogenetic analysis indicates that many B-myeloid
cases are characterized by t(9;22) or 11q23 abnormalities, while
T-myeloid cases exhibit frequent but generally non-recurring abnormali-
ties [11]. The hybrid transcript for BCR-ABL translocation [t (9, 22)] was
not found and no genomic breakpoints were noted, in further evaluation.
Pallor, lymphadenopathy, hepatosplenomegaly & fever were
conspicuous by their absence. There were no signs of hepatic
involvement either clinically or biochemically.
An ALL (Acute Lymphogenous Leukemia) regimen-CVD [Cyclophos-
phamide, Vincristine, Daunorubicin] was started with. No TKI-Tyrosine
Kinase Inhibitor (Imatinib) was added. In light of the poor response to
initial ALL regimens, the addition of AML [Acute Myelogenous Leuke-
mia] regimen [Idarubicin, cytosine and etoposide]was done. The patientFig. 2. ×1000 - Blasts having high nucleo-cytoplasmic ratio, scant agranular cytoplasm.
Nuclei are round with regular nuclear membrane, condensed chromatin.
Table 2
2008 WHO classiﬁcation of acute leukemias of ambiguous lineage.
Myeloid
lineage
Myeloperoxidase (ﬂow cytometry, immunohistochemistry or
cytochemistry)
or
Monocytic differentiation (at least two of the following: NSE, CD11c,
CD14, CD64, lysozyme)
T lineage Cytoplasmic CD3 (ﬂow cytometry with antibodies to CD3 epsilon
chain)
or
Surface CD3
B lineage Strong CD19 AND strong expression of at least one of the following:
CD79a,
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months.
The spinal leukemic deposit has diminished in size, but neurological
recovery in the paraplegic limbs is only modest at the best.
The child would have been a candidate for alloSCT (allogenic Stem
Cell Transplant), if these above strategies would have failed, for which
an HLA matched donor was made available. Intrathecal central nervous
system prophylaxiswas also givenwithmethotrexate or cytosine arabi-
noside; recombinant human granulocyte colony stimulating factor
(rhG-CSF) couldn't be administered because of socioeconomic reasons;
hematologic components were used instead.cytoplasmic CD22, CD10
or
Weak CD19 AND strong expression of at least two of the following:
CD79a, cytoplasmic CD22, CD102. Discussion
The greatmajority of acute leukemias can be unequivocally assigned
to the myeloid, B- or T-lymphoid lineage. However, with the
immunophenotypic markers typically used to characterize acute leuke-
mia, a small but heterogeneous subset of leukemias cannot be clearly
demarcated on these lines. Such tumours have been referred to as
acute leukemias of ambiguous lineage in the WHO classiﬁcation [2].
Ambiguous leukemias are rare and account for 4% of all cases of
acute leukemias and frequently demonstrate an aggressive disease
course with mean survival rates less than those of leukemias derived
from single cell lineage [6]. The numeric scoring system for deﬁning
MPALwas formulated by European Group for the immunological classi-
ﬁcation of leukemias (EGIL), Table 1. This scoring system is aimed at
distinguishing cases of MPAL from those with aberrant expression i.e.
Ly+ AML (AML with lymphoid markers) andMy+ ALL (ALL with my-
elogenous markers). Here MPAL or BAL is deﬁned, when the score from
two separate lineages is N2. Antigens detected by ﬂow cytometric
immunophenotyping were assigned a score of 2, 1 or 0.5, depending
on speciﬁcity of a particular antigen for myeloid, T lymphoid or B lym-
phoid lineage. Cases having a score of N2 in both lineages are designated
as biphenotypic [4].
EGIL has proposed standard criteria for the diagnosis of BAL, but
these criteria were mainly designed to recognize cases of antigen
coexpression, and did not explicitly address cases with dual leukemic
populations and distinguish them from those with shared antigens [1].
Early reports of biphenotypic and bilineal leukemia recognized these
two types of cases. The scoring system devised by EGIL attempted to
standardize a deﬁnition of biphenotypic leukemia, though it did not
clearly address bilineal cases. Several publications have appeared
using the EGIL criteria to describe series of BAL [8].
In the WHO 2008 classiﬁcation of leukemias of ambiguous lineage,
Table 2, the requirement for assigningmore than one lineage to a single
blast population has been depicted, Table 3. Broadly MPAL includes
Acute Undifferentiated Leukemia (AUL), MPAL with t (9; 22), MPAL
with t (v; 11q23), MPAL B/myeloid -NOS, MPAL T/myeloid -NOS,
MPAL –NOS, rare types and other ambiguous lineage leukemias. Leuke-
mias that switch their lineage of origin during therapy or show poorlyTable 1
The European Group for the Immunological Classiﬁcation of Leukemias (EGIL) scoring
system.
Points Myeloid B-lineage T-lineage
2 MPO CD79a
Cyt IgM
Cyt CD22
CD3,cyt and surface
TCR αβ
TCR γδ
1 CD13
CD33
CD65
CD19
CD10
CD20
CD2
CD5
CD8
CD10
0.5 CD14
CD15
CD64
CD117
TdT
CD24
TdT
CD7
CD1adifferentiated or undifferentiated features are also included in this cate-
gory [3].
Complete remission (CR) is deﬁned by the presence of b5% blasts in
the bone marrow, absence of extramedullary leukemia, and peripheral
blood count recovery with a neutrophil count of at least 1 × 109/L and
a platelet count of at least 100 × 109/L. MPAL/BAL patients showed a
much higher incidence of CD34 antigen expression, complex abnormal
karyotype, and extramedullary inﬁltration [13].
The optimal therapeutic approach to these cases, especially in paedi-
atric patients has not been deﬁned. It is still unclear whether patients
with biphenotypic leukemia fare better on induction regimes designed
for ALL or AML. Studies show poor treatment outcome in patients of
biphenotypic leukemia [9].
Considerable confusion still prevails regarding the optimal
management in absence of a distinct prospective, multi institutional
randomized controlled trial on this puzzling area in acute leukemia.
The nomenclature sounds similar, but the genotypic & the
immunophenotypicmanifestations varywidely; at the same timea con-
siderable overlap also exists between these entities in the published lit-
erature between the 2 classiﬁcation schema i.e. 1995, 2008. Multiple
single institute case series complicates the question of “THE OPTIMAL
MANAGEMENT” than trying to solve it. Nevertheless an initial ALL/
ALL + AML type induction regimen followed either by alloSCT/2nd
line chemotherapy, forms the backbone of all the suggested regimens.
Intention-to-treat analysis showed that treatment with ALL or ALL-
based approach, not AML protocol, resulted in high induction CR rates
in BAL patients, but the long-term survival was still dismal (Table 4)
[13].
Based on the experience and the pathology of BAL, Wang et.al. be-
lieve that a combined regimen for both AML and ALL might be the
best choice for the induction therapy for BAL, a unique entity with bio-
logical and clinical features of both myeloid and lymphoid leukemia.
The ALL or ALL-based induction regimens include anthracyclines and/
or Ara-C (Cytosine arabinoside). It has already been widely accepted
that anthracycline is a main component in the treatment of both AML
andALL. AML-type induction regimendid not include the effective com-
ponent such as steroids for ALL, so the outcome was poor [10].
“Mystique” is a ﬁctional supervillain appearing in American comic
books published by Marvel Comics, most commonly in association
with the X-Men [7]. In a similar manner, ‘MPAL-BAL-AUL-ALAL-aBLL-
HAL-MLL’ represent the most villainous bunch of entities amongst
acute lymphoblastic/myelogenous leukemias who require a lot of com-
plex tests to diagnose and another series of arduous chemotherapy in-
terventions before the patient actually attains CR.
MPAL is characterized by relative therapeutic resistance thatmay be
attributed in part to the high proportion of patients with adverse cyto-
genetic abnormalities [12]. It is unclear whether ALAL beneﬁts from an
AML- or ALL-based treatment protocol; this partly explains their
unfavourable prognosis.
Table 3
Lineage speciﬁc markers for lymphoid (B/T) & myeloid series.
Myeloid lineage
Myeloperoxidase (ﬂow cytometry, immunochemistry or cytochemistry)
or
Monocytic differentiation (at least 2 of the following: NSE, CD11c, CD14, CD64,
lysozyme)
T lineage
Cytoplasmic CD3 (ﬂow cytometry with antibodies to CD3 epsilon chain;
immunohistochemistry using polyclonal anti-CD3 antibody may detect CD3 zeta
chain, which is not T-cell speciﬁc)
or
Surface CD3 (rare in mixed phenotypic acute leukemia)
B lineage (multiple antigens required)
Strong CD19 with at least one of the following strongly expressed: CD79a,
cCD22,CD10
or
Weak CD19 with at least 2 of the following strongly expressed: CD79a, cCD22,
CD10
Table 4
Algorithm for management of MPAL.
MPAL with t(9,22)(q34, q1
Yes
Acute Lymphoblastic Leukemia (ALL) like 
chemotherapy + Tyrosine kinase Inhibitor (TKI)
No CR?
CR?
No CR?
Clinical trial or targeted therapy
Mixed Phenotypic Acute Le
-Reassess phenotype
-Assess for TKI resistant/change
TKI as indicated
-Considewr AML like salvage (High dose 
Cytarabine, Mitoxantrone-HAM)
Allogenic stem cell 
Relapse
Reasses phen
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(micro ribonucleotide acids) {miR-23a, miR-27a, miR-199b, miR-221,
and miR-223 by qRT-PCR (quantitative reverse transcriptase- polymer-
ase chain reaction)}, de Leeuw et al. were able to deﬁne MPAL/ALAL as
either AML or ALL. In conclusion, addition of miRNA evaluation to cur-
rent diagnostic procedures helps deciphering the myeloid or lymphoid
lineage predominance of an ALAL and thus the treatment of choice.
Moreover, usingmiRNA expression proﬁling to deﬁne subclasses of leu-
kemiamight bemore promising thanmRNA (messenger RNA) proﬁling
because miRNAs are more stable and can be used in smaller numbers
than the genes. The results indicated that leukemias of ambiguous line-
age are not a unique entity but could be classiﬁed as either AML or ALL
using miRNA expression proﬁling [5].
3. Conclusion
MPAL, BAL, AUL, ALAL, HAL, MLL and aBLL represent either expan-
sion of more than one clone of progenitor cells or expression of multi
lineage immunophenotypic markers [B/T/Myeloid]. Myriads of names
complicate strict taxonomical sub grouping as well as their manage-
ment. For routine neurosurgical practice, these entities are extremely
rare; and hence a working knowledge is very essential for appropriate1.2); BCR-ABL
No
CR? No
Yes
CR?
CR? No
ukemia (MPAL)
Acute Lymphoblastic Leukemia (ALL) like 
chemotherapy
-Reassess phenotype
-Considewr AML like salvage 
(High  dose Cytarabine, 
Mitoxantrone-HAM)
transplant
Clinical trial or targeted therapy
otype
79S.R. Tripathy et al. / Interdisciplinary Neurosurgery: Advanced Techniques and Case Management 6 (2016) 75–79& timely management notwithstanding the neurosurgical desire to rule
out the compressive lesions ﬁrst. Neurological status deterioration may
be halted with timely chemotherapy. In the extensive literature review
in pubmed, this may be only the 1st case of MPAL with extramedullary
neurological manifestation, at the ﬁrst clinical presentation.
Finally, a distinct prospective, multi institutional randomized con-
trolled trial on this puzzling area in acute leukemia, assimilating both
AML+ALL induction regimens aswell asmiRNAs studies,may be hold-
ing the lamp for futuristic and more accurate treatment protocols.Patient Consent
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Background
MPAL (Multi Phenotypic Acute Leukemia), BAL (Biphenotypic Acute
Leukemia), AUL (Acute Undifferentiated Leukemia), ALAL (Acute Leuke-
mia of Ambiguous Lineage), HAL (Hybrid Acute Leukemia),MLL (Mixed
Lineage Leukemia) and aBLL (acute BiLineal Leukemia): - these are
some of the descriptive terms used to describe this rather rare acute leu-
kemiaswhere expansion ofmore than one clone of progenitor cells or ex-
pression of multi lineage immunophenotypic [B/T/Myeloid] markers.
A 16 year female presented with gradual onset paraplegia for 7
months, a history ofmultiple blood transfusions in the past 2 years, pan-
cytopenia, atypical cells in peripheral smear; the hematological and
bone marrow work up revealed a diagnosis of:MPAL, B/Myeloid, NOS
[Multi Phenotypic Acute Leukemia, B cell {lymphoid}/Myeloid, not oth-
erwise speciﬁed]. An ALL type induction regimenwas started. Theman-
agement strategy, its rationale and the clinical outcome are discussed.
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